Claritev Corporation (CTEV) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Claritev Corporation stock $68.13, price $22.71, upside +200.0%, quality 33 out of 100. Rating: strongly undervalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range $5.21 – $289.60 · fair‑value band $16.18 – $120.08 · the $22.71 price screens below the $68.13 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Claritev in your weekly email
Every Wednesday you see whether Claritev is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States.
Show moreShow less
The company offers claims intelligence solutions, including reference-based pricing, negotiation services, surprise bill services, and Vistara; network solutions, such as primary networks, complementary networks, and network build and network management services; and payment and revenue integrity solutions comprising clinical negotiation, pre-payment integrity, post-payment integrity, and revenue integrity services.
It also provides data and analytics solutions consists of PlanOptix, CompleteVue, BenInsights, risk scores, and supplemental carrier services.
The company provides solutions to commercial healthcare payers, third party administrators, employers, brokers/consultants, providers, government healthcare payers and system integrators.
It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, property and casualty insurers, bill review companies and other companies involved in the claims adjudication process.
The company was formerly known as MultiPlan Corporation and changed its name to Claritev Corporation in February 2025. Claritev Corporation was founded in 1980 and is headquartered in McLean, Virginia.
Stock analysis
Claritev Corporation (CTEV) currently trades at $22.71, while our model-based Fair Value estimate is $68.13, implying the stock looks roughly 67% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $16.18 (bear) to $120.08 (bull), the price of $22.71 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Claritev Corporation reported revenue of $965M in FY2025 versus $1.1B in FY2021, a compound −3.6%/yr. Reported net income was −$284M in FY2025.
Key figures
Market cap $385M Small · P/S ratio 0.39 · EPS (TTM) $−17.00 · Net margin −28.5% · Return on equity −646% · Return on assets (EBIT) −4.8% (5-year average) · Operating margin 12.8% · Revenue (TTM) $995M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).
What moves the price
The share trades about 67% below its 52-week high and 69% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at 200%, CTEV screens cheaper than that median.
Fair Value models
Bear$16.18Fair Value $68.13Bull$120.08
Price $22.71 · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 4 officers or directors bought shares worth $743,128, most recently on Aug 28, 2026. Over the same period, 3 people sold shares worth $1.1M. Buying cluster
BuyARES MANAGEMENT LLC10% owner2× since Oct 23, 2026: 141,668 shares, avg. $23.69$3.4MOct 26, 2026
SaleTiffani MisencikSVP, Chief Growth Officer2× since Aug 14, 2026: 14,662 shares, avg. $33.62$493,010Oct 15, 2026
SaleDouglas Michael GarisEVP&CFO9,025 shares at $30.59$276,055Sep 21, 202610b5-1 plan
BuyTravis DaltonPres., CEO & Executive Chair, Director4× since Nov 20, 2025: 48,040 shares, avg. $19.94$958,106Aug 28, 2026
SaleWilliam B. MintzSVP, Chief Strategy Officer8,431 shares at $34.24$288,677Aug 10, 2026
BuyNutter CarolSVP, Chief People Officer875 shares at $28.41$24,859Jun 9, 2026
BuyJohn Michael PrinceDirector10,000 shares at $16.00$160,000May 19, 2026
BuyMichael KimEVP, Chief Digital Officer4× since Nov 17, 2025: 57,600 shares, avg. $18.99$1.1MMay 18, 2026
BuyDouglas Michael GarisEVP&CFO1,300 shares at $17.69$22,997Mar 16, 2026
BuyTara O'NeilSVP, General Counsel2× since Nov 17, 2025: 1,375 shares, avg. $24.74$34,018Mar 2, 2026
Plus 2 more entries from the last 12 months.
Plus 6 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.12/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+3.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.6%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.1%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−14.1% (2020) → 4.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 118 stocks
Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score33 · Bottom 25%
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (12 months)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−5.8% · Below median
Net margin (12 months)−28.5% · Bottom 25%
Operating margin (12 months)12.8% · Above median
Growth and dividend
Revenue growth (quarter YoY)6.6% · Below median
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months)0.39× · Cheapest 25%
EV/EBITDA9.2× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)100· sector 0
FUTURE (revenue growth)33· sector 48
PAST (return on equity)0· sector 10
HEALTH (low debt)0· sector 98
DIVIDEND (yield)0· sector 41
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Claritev Corporation Fair Value". https://www.fairvalue-calculator.com/stock/CTEV
Frequently asked questions
Is Claritev Corporation (CTEV) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $68.13 versus a price of $22.71, about +200% upside (undervalued).
What is the fair value of CTEV?
Our model-based fair value for Claritev Corporation is $68.13 (as of Nov 8, 2026), built from audited fundamentals. The current price: $22.71.
What is the quality score of CTEV?
Claritev Corporation has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Claritev Corporation (CTEV)?
Our model-based price target is the fair value of $68.13 (as of Nov 8, 2026) from 2 valuation models. Cautious scenario $16.18, optimistic scenario $120.08. It is a calculation from audited fundamentals, not an analyst target.
What is the Claritev Corporation stock forecast for 2026?
Our models put fair value at $68.13, about +200% upside versus a price of $22.71 (undervalued). Cautious scenario $16.18, optimistic scenario $120.08. The calculation is refreshed regularly with new filings.
What is the revenue of Claritev Corporation (CTEV)?
Claritev Corporation reported trailing-twelve-month revenue of about $995M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Claritev Corporation (CTEV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Claritev Corporation it is $68.13 per share (as of Nov 8, 2026), against a price of $22.71. It is the blended result of 2 valuation models in 2 families (DCF Models, Multiples).
Is Claritev Corporation stock overvalued or undervalued in 2026?
As of Nov 8, 2026, CTEV trades below its calculated fair value: price $22.71, fair value $68.13, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CTEV?
No. The price is what the market pays today ($22.71); the fair value is what the company's own numbers justify ($68.13). For Claritev Corporation the two are $45.42 per share apart. That gap is exactly why we show both numbers side by side.
How much is Claritev Corporation worth?
The market values Claritev Corporation at about $385M (market capitalisation, as of Nov 8, 2026). Per share that is $22.71; our models calculate a fair value of $68.13 per share.
What do the bullish and bearish scenarios say about CTEV?
Our models span a range for Claritev Corporation: cautious scenario $16.18, base $68.13, optimistic $120.08 per share (as of Nov 8, 2026, price $22.71). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Claritev Corporation (CTEV)?
Balance-sheet figures for Claritev Corporation (as of Nov 8, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is CTEV from its 52-week high?
Claritev Corporation trades at $22.71, about 67% below its 52-week high of $69.25 and 69% above the low of $13.47 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $68.13 is for.
Which stocks are comparable to Claritev Corporation?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Claritev Corporation stock attractive at the current price?
The data as of Nov 8, 2026: price $22.71, calculated fair value $68.13 (+200%), Quality Score 33/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CTEV calculated?
We run Claritev Corporation through 2 models from 2 families: DCF Models, Multiples. Every model gets the same audited fundamentals; the fair value of $68.13 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Claritev Corporation currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Claritev Corporation (CTEV)?
The closing price on Nov 6, 2026 was $22.71. Our model-based fair value is $68.13, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Claritev Corporation right now?
The large discount to fair value meets weak quality (33/100). That raises the risk this is a value trap rather than a bargain. The model range is unusually wide ($16.18 to $120.08). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Claritev Corporation
How large is the market capitalisation of Claritev Corporation (CTEV)?
The market capitalisation of Claritev Corporation is $385M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Claritev Corporation (CTEV)?
The price-to-sales ratio of Claritev Corporation is 0.39 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Claritev Corporation (CTEV)?
Earnings per share at Claritev Corporation are $−17.00. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Claritev Corporation (CTEV)?
The net margin of Claritev Corporation is −28.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Claritev Corporation (CTEV)?
The return on equity (ROE) of Claritev Corporation is −646% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Claritev Corporation (CTEV)?
On an EBIT basis the return on assets of Claritev Corporation is −4.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Claritev Corporation (CTEV)?
The operating margin of Claritev Corporation is 12.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Claritev Corporation (CTEV)?
Revenue at Claritev Corporation is growing +6.6% versus a year earlier (3y avg −3.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Claritev Corporation (CTEV) generate?
The free cash flow of Claritev Corporation is −$12.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Claritev Corporation (CTEV) carry?
The net debt of Claritev Corporation is $4.6B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Claritev Corporation in the live analysis
One click puts Claritev Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026
